Top Deck Moves At Ranbaxy: Jay Deshmukh, Architect Of Lipitor And Nexium Patent Challenge Quits, R&D Head Himadri Sen Turns Advisor
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Japanese drug maker Daiichi Sankyo's acquisition of India's largest company - Ranbaxy - could result in a few structural changes in the company's top management team